Viking Therapeutics, Inc VKTX

Viking Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que se enfoca en el desarrollo de terapias para el tratamiento de trastornos metabólicos y endocrinos. Los programas clínicos de la compañía incluyen VK2809, un agonista selectivo del receptor beta de la hormona tiroidea de molécula pequeña disponible por vía oral para el tratamiento de trastornos lipídicos y metabólicos, que está siendo evaluado en un estudio de Fase IIb para el tratamiento de esteatohepatitis no alcohólica (NASH) y fibrosis confirmada por biopsia. La compañía está desarrollando VK0214, que también es un agonista selectivo de tejido y subtipo de receptor de TRb disponible por vía oral para la adrenoleucodistrofia ligada al cromosoma X (X-ALD), un trastorno neurológico hereditario raro ligado al cromosoma X caracterizado por una ruptura en las barreras protectoras que rodean las células cerebrales y nerviosas. También está desarrollando VK2735, un agonista dual de los receptores del péptido similar al glucagón 1 (GLP-1) y del péptido insulinotrópico dependiente de glucosa (GIP) para el tratamiento de diversos trastornos metabólicos.

• The Motley Fool 2 oct

  Prediction: This Stock Could Double Over the Next 5 Years

  Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

  

• Zacks Investment Research 1 oct

  Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

  Viking Therapeutics (VKTX) stock declined 6.41% on October 1, 2026, underperforming the broader market which gained 0.2%. The company is expected to report negative EPS of -$1 for the upcoming quarter, down 23.46% year-over-year, with full-year earnings forecasted at -$4.47 per share. Despite the losses, VKTX maintains a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 27% of all sectors.

  

• The Motley Fool 29 sept

  Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

  Viking Therapeutics released impressive clinical trial results for its weight-loss drug VK2735, showing 16-19% body weight loss and strong maintenance results. However, Eli Lilly's stock barely moved because the company has its own robust maintenance strategies (Foundayo and dose reduction approaches) and a deeper pipeline. While Viking could become a competitor in the growing weight-loss market, it still needs to confirm results in larger Phase 3 trials, and Eli Lilly remains the safer, more established choice.

  

• The Motley Fool 28 sept

  Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

  Viking Therapeutics' GLP-1 drug VK2735 showed promising clinical trial results with 16-19% weight loss and strong maintenance rates, causing the stock to surge. While riskier than Eli Lilly due to its smaller $4.1B market cap and lack of approved drugs, Viking could offer significant upside potential through drug approval or acquisition by a larger healthcare company.

  

• The Motley Fool 25 sept

  Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

  Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.